Vaxart, Inc. (NASDAQ:VXRT) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET

Company Participants

Edward Berg - Senior Vice President and General Counsel
Steven Lo - Chief Executive Officer
James Cummings - Chief Medical Officer
Sean Tucker - Senior Vice President and Chief Scientific Officer
Phillip Lee - Chief Financial Officer

Conference Call Participants

Cheng Li - Oppenheimer
Mayank Mamtani - B. Riley Securities
Liang Cheng - Jefferies

Operator

Greetings and welcome to the Vaxart Business Update and Third Quarter 2024 Financial Results Conference Call. A question-and-answer session will follow management's opening remarks. Individual investors may submit written questions to IR at vaxart.com. As a reminder, this conference is being recorded.

I would now like to turn the webcast over to your host Ed Berg, Senior Vice President and General Counsel.

Edward Berg

Good afternoon and welcome to today's call. Joining us from Vaxart are Steven Lo, Chief Executive Officer; Dr. Sean Tucker, Founder and Chief Scientific Officer; Dr James Cummings, Chief Medical Officer; and Phil Lee, Chief Financial Officer.

Before we begin, I would like to remind everyone that during this conference call, Vaxart may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations, and its product development and regulatory progress, including statements about its ongoing or planned clinical trials.

Actual results could materially differ from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process and other risks described in the Risk Factors section of Vaxart's most recently filed annual report on Form 10-K, and also on other periodic reports filed with the SEC. Vaxart undertakes no obligation to update any forward-looking statements after the date of this call.

I'll now turn the call over to Steven Lo. Steve?

Steven Lo

Thanks, Ed, and thanks to all of you for joining us this afternoon. On today's call, I'm excited to highlight a number of accomplishments that we have achieved since our last update. I'll then have James and Sean share updates on our COVID, Norovirus and HPV programs respectively. Then Phil will discuss our financial results before we open the call for your questions.

When I joined Vaxart earlier this year, we set out clear objectives with the goal of advancing our oral pill vaccine platform and bringing a potentially transformative solution to improve public health. Not only does our platform show promise in addressing many of the shortcomings of injectable vaccines such as using mucosal immunity to potentially block infection and transmission, but it also improves delivery convenience and has demonstrated a benign safety and tolerability profile across 19 clinical trials to-date.